CN111741946A - 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用 - Google Patents

吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用 Download PDF

Info

Publication number
CN111741946A
CN111741946A CN201880057640.2A CN201880057640A CN111741946A CN 111741946 A CN111741946 A CN 111741946A CN 201880057640 A CN201880057640 A CN 201880057640A CN 111741946 A CN111741946 A CN 111741946A
Authority
CN
China
Prior art keywords
alkyl
compound
radical
cancer
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880057640.2A
Other languages
English (en)
Other versions
CN111741946B (zh
Inventor
李磐
温俏冬
王骥
甘泉
路杨
杨东晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen Baotai Biotechnology Co ltd
Original Assignee
Hangzhou Arnold Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Arnold Biomedical Technology Co ltd filed Critical Hangzhou Arnold Biomedical Technology Co ltd
Priority to CN202010446435.4A priority Critical patent/CN111471011B/zh
Priority to CN202010446383.0A priority patent/CN111471010B/zh
Priority to CN202010446396.8A priority patent/CN111574442A/zh
Priority to CN202010446382.6A priority patent/CN111471035B/zh
Publication of CN111741946A publication Critical patent/CN111741946A/zh
Application granted granted Critical
Publication of CN111741946B publication Critical patent/CN111741946B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及式I所示的化合物，包含所述式I化合物的药物组合物，其抑制吲哚胺2,3‑双加氧酶的方法以及其在医学上的用途。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201880057640.2A 2017-12-29 2018-12-27 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用 Active CN111741946B (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN202010446435.4A CN111471011B (zh) 2017-12-29 2018-12-27 高活性吲哚胺2,3-双加氧酶抑制剂的制备方法
CN202010446383.0A CN111471010B (zh) 2017-12-29 2018-12-27 吲哚胺-2,3-双加氧酶(ido)抑制剂的制备方法
CN202010446396.8A CN111574442A (zh) 2017-12-29 2018-12-27 吲哚胺2,3-双加氧酶抑制剂的制备方法
CN202010446382.6A CN111471035B (zh) 2017-12-29 2018-12-27 一类ido抑制剂的制备方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017114783072 2017-12-29
CN201711478307 2017-12-29
CN201810754253 2018-06-29
CN2018107542536 2018-06-29
PCT/CN2018/124110 WO2019129114A1 (zh) 2017-12-29 2018-12-27 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用

Related Child Applications (4)

Application Number Title Priority Date Filing Date
CN202010446435.4A Division CN111471011B (zh) 2017-12-29 2018-12-27 高活性吲哚胺2,3-双加氧酶抑制剂的制备方法
CN202010446383.0A Division CN111471010B (zh) 2017-12-29 2018-12-27 吲哚胺-2,3-双加氧酶(ido)抑制剂的制备方法
CN202010446396.8A Division CN111574442A (zh) 2017-12-29 2018-12-27 吲哚胺2,3-双加氧酶抑制剂的制备方法
CN202010446382.6A Division CN111471035B (zh) 2017-12-29 2018-12-27 一类ido抑制剂的制备方法

Publications (2)

Publication Number Publication Date
CN111741946A true CN111741946A (zh) 2020-10-02
CN111741946B CN111741946B (zh) 2022-09-23

Family

ID=67063216

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880057640.2A Active CN111741946B (zh) 2017-12-29 2018-12-27 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用

Country Status (5)

Country Link
US (1) US11111230B2 (zh)
CN (1) CN111741946B (zh)
GB (1) GB2583606C (zh)
TW (1) TWI827576B (zh)
WO (1) WO2019129114A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180497B2 (en) * 2017-10-18 2021-11-23 Angex Pharmaceutical, Inc. Cyclic compounds as immunomodulating agents
KR20210066857A (ko) * 2018-09-27 2021-06-07 쉔젠 칩스크린 바이오사이언스 씨오., 엘티디. 인돌아민-2,3-디옥시게나아제 억제 활성을 갖는 퀴놀린 유도체

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678586A (zh) * 2002-06-27 2005-10-05 舍林股份公司 取代的喹啉ccr5受体拮抗剂
CN101479249A (zh) * 2006-06-29 2009-07-08 霍夫曼-拉罗奇有限公司 苯并咪唑衍生物、其制备方法、它们作为fxr激动剂的用途及含有它们的药物制剂
WO2013134518A1 (en) * 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
WO2017192813A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107427499A (zh) * 2014-11-05 2017-12-01 弗莱塞斯生物科学公司 免疫调节剂
CN107663159A (zh) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
CN111263752A (zh) * 2017-10-30 2020-06-09 葛兰素史克知识产权开发有限公司 吲哚胺 2,3-双加氧酶的调节剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11180497B2 (en) * 2017-10-18 2021-11-23 Angex Pharmaceutical, Inc. Cyclic compounds as immunomodulating agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1678586A (zh) * 2002-06-27 2005-10-05 舍林股份公司 取代的喹啉ccr5受体拮抗剂
CN101479249A (zh) * 2006-06-29 2009-07-08 霍夫曼-拉罗奇有限公司 苯并咪唑衍生物、其制备方法、它们作为fxr激动剂的用途及含有它们的药物制剂
WO2013134518A1 (en) * 2012-03-09 2013-09-12 Amgen Inc. Sulfamide sodium channel inhibitors
CN107427499A (zh) * 2014-11-05 2017-12-01 弗莱塞斯生物科学公司 免疫调节剂
WO2017192813A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107663159A (zh) * 2016-07-29 2018-02-06 上海迪诺医药科技有限公司 多环化合物、其药物组合物及应用
CN111263752A (zh) * 2017-10-30 2020-06-09 葛兰素史克知识产权开发有限公司 吲哚胺 2,3-双加氧酶的调节剂

Also Published As

Publication number Publication date
TWI827576B (zh) 2024-01-01
GB2583606A (en) 2020-11-04
TW201930268A (zh) 2019-08-01
US11111230B2 (en) 2021-09-07
CN111741946B (zh) 2022-09-23
GB2583606B (en) 2021-04-21
GB202009911D0 (en) 2020-08-12
GB2583606C (en) 2021-10-27
WO2019129114A1 (zh) 2019-07-04
US20200331887A1 (en) 2020-10-22

Similar Documents

Publication Publication Date Title
US11013726B2 (en) Substituted pyridinone-containing trycyclic compounds, and methods using same
TWI551595B (zh) 2,4-disubstituted benzene-1,5-diamine derivatives and their use, Its preparation of pharmaceutical compositions and pharmaceutical compositions
KR20210121168A (ko) 복소환식 화합물인 벤조피리돈 및 그 사용
CN114728968A (zh) 稠合吡啶酮类化合物及其制备方法和应用
JP2023523640A (ja) ベンゾチアゾリルビアリール系化合物、その調製方法及び使用
CN112778276A (zh) 作为shp2抑制剂的化合物及其应用
US10662173B2 (en) Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
AU2014221775A1 (en) TETRAHYDROIMIDAZO[1,5-d][1,4]OXAZEPINE DERIVATIVE
CN111518076B (zh) 具有吲哚胺-2,3-双加氧酶(ido)抑制剂的制备方法
WO2019177937A1 (en) Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
CN112804995A (zh) 隐杯伞素类似物、其应用及其合成方法
CN111741946B (zh) 吲哚胺2,3-双加氧酶抑制剂以及它们在医学上的应用
JP2022515890A (ja) エストロゲン受容体タンパク質分解薬
JP6838045B2 (ja) 化合物
KR20220053637A (ko) 치환된 우레아 다이하이드로오로테이트 탈수소효소 억제제
EP1572672A1 (en) Benzoxazocines and their use as monoamine-reuptake inhibitors
WO2023064586A1 (en) Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof
TWI803511B (zh) 嗎啉基吡啶酮化合物
WO2024088408A1 (zh) 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用
EP3189061A1 (fr) Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques comme inhibiteurs de la ftl3 et jak
EP4159736A1 (en) Novel tricyclic aromatic heterocyclic compound and preparation method therefor, pharmaceutical composition and use thereof
NZ793890A (en) Substituted pyridinone-containing tricyclic compounds, and methods using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 310000 Building 8, No. 1008, Longxiang street, Cangqian street, Yuhang District, Hangzhou City, Zhejiang Province

Applicant after: Hangzhou Arnold Biomedical Technology Co.,Ltd.

Address before: 310018 21st floor, building 2, 452, 6th Street, Qiantang New District, Hangzhou, Zhejiang Province

Applicant before: Hangzhou Arnold Biomedical Technology Co.,Ltd.

CB02 Change of applicant information
TA01 Transfer of patent application right

Effective date of registration: 20211129

Address after: 361000 floor 3-5, No. 188, Pingcheng South Road, Haicang street, Haicang District, Xiamen City, Fujian Province

Applicant after: Xiamen Baotai Biotechnology Co.,Ltd.

Address before: 310000 Building 8, No. 1008, Longxiang street, Cangqian street, Yuhang District, Hangzhou City, Zhejiang Province

Applicant before: Hangzhou Arnold Biomedical Technology Co.,Ltd.

TA01 Transfer of patent application right
GR01 Patent grant
GR01 Patent grant